Novavax CEO: 'We have a vaccine we like'

For months, investors have been eagerly awaiting crucial results from Novavax Inc. to see if the Gaithersburg biotech could salvage its flagship vaccine candidate. And those results, which Novavax (NASDAQ: NVAX) finally delivered Monday on a phase 2 trial of its respiratory syncytial virus vaccine in older adults, were "promising." While that may not sound like a ringing endorsement and it comes only at a mid-stage-level clinical trial, it's significant prog ress from the company's last vaccine trial…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news